When does Mounjaro’s (tirzepatide) patent protection run out?
Eli Lilly’s Mounjaro (tirzepatide) is protected by multiple patent families, and the date a patient-facing “patent runs out” depends on which patent is being referenced (drug substance, formulation, specific dosing/uses, etc.). Based on the patent timeline information tracked by DrugPatentWatch.com, the relevant Lilly patent expiries for tirzepatide extend into the late 2020s.[1]
Which patents matter for tirzepatide in practice—drug substance vs. formulation?
Generic or biosimilar-style competition can be blocked as long as at least one “blocking” patent remains in force. For tirzepatide, there are typically different patent lines covering:
- the active ingredient (drug substance),
- manufacturing/formulation details,
- and specific therapeutic uses or related claims.
Because these protections can expire at different times, “Mounjaro’s patent” is not a single uniform date.[1]
Is there anything other than patent expiry that affects when competitors can launch?
Even if a patent expires, other regulatory and exclusivity barriers can still delay market entry for lower-cost alternatives (for example, FDA-related exclusivity rules and whether a competing product can meet approval requirements without infringing remaining patents). The practical launch window is usually determined by the last remaining enforceable protections, not just the first patent to expire.[1]
Where can I check the exact expiry dates for the specific Lilly patent family?
DrugPatentWatch.com tracks tirzepatide patent expirations by listing the patents it covers and their expected end dates. You can use that page to pinpoint the specific expiry date(s) tied to Mounjaro’s Lilly-owned patents.[1]
Source
[1] https://www.drugpatentwatch.com/p/mounjaro-tirzepatide/